Distinct Agonist Regulation of Muscarinic Acetylcholine M_2-M_3 Heteromers and Their Corresponding Homomers

Despoina Aslanoglou, Elisa Alvarez-Curto, Sara Marsango, and Graeme Milligan

From the Molecular Pharmacology Group, Institute of Molecular, Cell, and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom

Results:
Co-expression of M_2 and M_3 receptors resulted in concurrent detection of both homomer and heteromer interactions and regulation of M_2-containing forms by agonist.

Conclusion:
Co-existing receptor oligomers display differential regulation.

Significance:
Oligomers of closely related receptors display distinct properties that may be targeted therapeutically.

Each subtype of the muscarinic receptor family of G protein-coupled receptors is activated by similar concentrations of the neurotransmitter acetylcholine or closely related synthetic analogs such as carbachol. However, pharmacological selectivity can be generated by the introduction of a pair of mutations to produce Receptor Activated Solely by Synthetic Ligand (RASSL) forms of muscarinic receptors. These display loss of potency for acetylcholine/carbachol alongside a concurrent gain in potency for the ligand clozapine N-oxide. Co-expression of a form of wild type human M_2 and a RASSL variant of the human M_3 receptor resulted in concurrent detection of each of M_2-M_2 and M_3-M_3 homomers alongside M_2-M_3 heteromers at the surface of stably transfected Flp-In™ T-REx™ 293 cells. In this setting occupancy of the receptors with a muscarinic antagonist was without detectable effect on any of the muscarinic oligomers.

However, selective agonist occupancy of the M_2 receptor resulted in enhanced M_2-M_2 homomer interactions but decreased M_2-M_3 heteromer interactions. By contrast, selective activation of the M_3 RASSL receptor did not significantly alter either M_3-M_3 homomer or M_2-M_3 heteromer interactions. Selectively targeting closely related receptor oligomers may provide novel therapeutic opportunities.

Members of the family of muscarinic acetylcholine receptors constitute models for understanding more broadly the superfamilies of rhodopsin-like G protein-coupled receptors (GPCRs) in terms of signaling, structure and pharmacology (1–3). The existence of complexes between muscarinic receptors, in the form of homomers and heteromers has been reported previously (4–9) and the basis and importance of dimerization/oligomerization involving members of this group of GPCRs has been discussed extensively (10–12).

The growing availability of crystal structures of different rhodopsin-like GPCRs has, in many cases, shown potential interaction interfaces between monomeric units (13–15). However, it remains uncertain if these are of physiological significance or simply reflect the most effective way of producing a crystal lattice. Moreover, it is clear that purified and reconstituted monomeric units of such receptors are able to interact with heterotrimeric G proteins in a manner that is regulated by guanine nucleotides and, therefore, in a functionally relevant manner (16–17). In addition to this, there are widely conflicting views on the stability of GPCR-GPCR interactions (18–21), whether this varies substantially within closely related groups of GPCRs, and on the effects or otherwise of receptor ligands on such interactions (see Ref. 11 for review). Furthermore, although it is widely accepted that co-expression of pairs of GPCRs that are able to interact may result in the concurrent presence of each of heteromers containing both GPCRs as well as the corresponding homomers, this has been challenging to demonstrate directly (22). Herein, we use co-expression of forms of the human muscarinic M_2 and M_3 receptors to explore these issues.

We demonstrate concurrent detection of M_2-M_2, M_3-M_3, and M_2-M_3 interactions at the surface of cells and distinct agonist regulation of these interactions.

Experimental Procedures

Materials—Materials for cell culture were from Sigma Aldrich or Life Technologies unless otherwise stated. Clozapine N-oxide (CNO) was from Enzo Life Sciences. Carbachol and atropine were from Sigma-Aldrich. Immunological reagents able to identify the epitope tags were obtained from New England Biolabs (anti-SNAP) or Roche (anti-HA). The antisum directed against VSV epitope was produced in-house. All secondary IgG, horseradish peroxidase-linked antibodies were from GE Healthcare. The radioligand [(3H]quinuclidinylbenzilate ([3H]QNB) was from PerkinElmer. Flp-In™ T-REx™ 293 cells were from Life Technologies.

Molecular Constructs—Generation of the human (h)M_2 RASSL mutant was described by Ref. 4. HA-CLIP-hM_2 RASSL and...
Regulation of Muscarinic Receptor Oligomers

VSV-SNAP-hM2WT cDNA constructs were produced by introducing the metabotropic glutamate 5 receptor (mGluR5) signal sequence followed by either the VSV and SNAP tags or the hemaglutinin (HA) and CLIP tags into the N terminus of the hM2WT or hM3RASSL receptor, respectively (4, 23).

Generation of Flp-In™ T-Rex™ 293 Cells Stably Expressing Muscarinic Receptor Constructs—Cells were maintained in complete Dulbecco’s modification of Eagle’s medium (DMEM) without sodium pyruvate, 4500 mg l−1 glucose, and L-glutamine, supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) penicillin/streptomycin mixture, 200 µg ml−1 hygromycin B, and 10 µg ml−1 blasticidin in a humidified atmosphere. Single stable Flp-In™ T-Rex™ 293 cell lines able to inducibly express the different cDNA constructs were generated as described previously (4, 22–23). To constitutively co-express a second receptor construct in these cells they were transfected with the appropriate cDNA construct, as described above, and antibiotic-resistant clones selected using 1 mg ml−1 G418. All such cell lines were initially screened by fluorescence microscopy for receptor expression based on covalent binding of SNAP- or CLIP-tagged fluorophores and subsequently by measuring specific binding of [3H]QNB in cell membrane preparations.

Cell Membrane Preparations—Cells treated or not with doxycycline, were harvested after 24 h, in ice-cold phosphate-buffered saline (PBS) and pelleted were frozen at −80 °C for a minimum of 1 h. Pellets were thawed and resuspended in ice-cold 10 mM Tris, 0.1 mM EDTA, pH 7.4 (TE) buffer, supplemented with Complete™ protease inhibitor mixture (Roche Diagnostics). Cells were passed through a 25-gauge needle (5–10 times) and then homogenized on ice, by 50 strokes in a glass-on-teflon homogenizer. Homogenized cells were centrifuged at 200 × g for 5 min at 4 °C. The supernatant fraction was removed and transferred to microcentrifuge tubes and subjected to further centrifugation at 90,000 × g for 45 min at 4 °C. The pellets were resuspended in TE buffer, and protein concentration was assessed. Membrane preparations were either used directly or kept at −80 °C until required.

Radioligand Binding Studies—Binding using various concentrations of [3H]QNB was carried out using 5 µg of membrane protein per reaction in assay buffer (20 mM HEPES, 100 mM NaCl, 10 mM MgCl2, pH 7.4). Non-specific binding was defined in the presence of 10 µM atropine. Reactions were incubated for 2 h at 30 °C. Bound ligand was separated from free by vacuum filtration through GF/C filters (Brandel Inc.). The filters were washed twice with assay buffer, and bound ligand was estimated by liquid scintillation spectrometry.

Cell Lysate Preparation and Immunoblotting—Cells were harvested, washed twice in ice cold PBS, and pelleted by centrifugation. The pellets were resuspended in radio-immunoprecipitation buffer (50 mM HEPES, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 10 mM NaF, 5 mM EDTA, 10 mM Na2HPO4, 5% ethylene glycol, pH 7.4), supplemented with Complete™ protease inhibitors mixture. Resuspended cells were then placed on a rotating wheel for 30 min at 4 °C, and subsequently centrifuged at 21,000 × g, for 15 min at 4 °C. Supernatants were collected, and the protein concentration of the lysates determined. Samples were heated at 60–65 °C in 1× Laemml buffer (10% w/v SDS, 10 mM dithiothreitol, 20% v/v glycerol, 0.2 M Tris-HCl, 0.05% w/v bromphenol blue, pH 6.8). The required amount of protein lysate was then loaded on 4–12% NuPAGE™ Novex® Bis-Tris gels (Life Technologies).

Following electrophoresis, proteins were transferred onto a nitrocellulose membrane, blocked, and subsequently incubated with the primary antibody/antiserum in 5% fat-free milk TBST (2 mM Tris-base, 15 mM NaCl, and 0.1% v/v Tween 20, pH 7.4) at 4 °C, overnight. After 5 × 5 min washing steps with TBST, the appropriate horseradish peroxidase-conjugated IgG secondary antibody was incubated with the membrane at room temperature for 1 h. Immunoblots were developed using enhanced chemiluminescence solution (Pierce).

Epifluorescence Imaging of Living Cells—Cells were seeded on poly-D-lysine pre-coated cover slips (0.0 mm thickness) to 500,000 cells per cover slip and incubated overnight in the presence or absence of doxycycline in complete DMEM. Cells that expressed HA-CLIP-hM,RASSL receptor were labeled with 5 µM CLIP-Surface 488 while those expressing VSV-SNAP-hM2WT were labeled using 5 µM SNAP-Surface 549 (New England Biolabs) in complete DMEM for 30 min at 37 °C in 5% CO2. Cells were washed three times with complete DMEM and once with HEPES physiological saline solution (130 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, pH 7.4, and 10 mM d-glucose). Cover slips were imaged using an inverted Nikon TE2000-E microscope (Nikon Instruments, Melville, NY) equipped with a 40× (numerical aperture-1.3) oil-immersion Pan Fluor lens and a cooled digital Photometrics Cool Snap-HQ charge-coupled device camera (Roper Scientific, Trenton, NJ).

Homogeneous Time-resolved FRET (htrFRET)—Cells were grown to 100,000 per well on poly-D-lysine pre-treated 96-well solid black bottom plates (Greiner Bio-One). Cells were induced with doxycycline at the stated concentration for 24 h to express the receptor(s) of interest. After 24 h induction, cell surface receptor expression was monitored by adding 10 nM SNAP-Lumi4Tb or 20 nM CLIP-Lumi4Tb. After incubation at 37 °C/5% CO2 for 1 h, cells were washed three times with labeling medium (Cisbio Bioassays), and the fluorescence output was read at 620 nm using a PheraStar FS (BMG Lab technologies).

In htrFRET experiments various combinations of energy donor:acceptor were used to detect either homomers or heteromers. Detection of hM2WT homomers was carried out by labeling with 5 nM SNAP-Lumi4Tb with varying concentrations of SNAP-Red. hM3RASSL homomers were detected by labeling with 10 nM CLIP-Lumi4Tb and varying concentrations of CLIP-Red. Heteromeric interactions between hM2WT and hM3RASSL were detected using 5 nM SNAP-Lumi4Tb with varying concentrations of CLIP-Red, or the reverse combination, 10 nM CLIP-Lumi4Tb with varying concentrations of SNAP-Red. Labeling reactions were carried out for 1 h at 37 °C/5% CO2. Cells were then washed three times with 100 µl per well labeling medium and plates were either read directly after this or further processed to test the effect of receptor ligands. For the latter experiments, ligands were added to the plates after the washing step and subsequently incubated at the noted temperature and times prior to measurements using a
Regulation of Muscarinic Receptor Oligomers

To explore aspects of the potential oligomerization of the wild type (WT) human (h) muscarinic M2 acetylcholine receptor, a construct (VSV-SNAP-hM2WT) was generated in which the extracellular N-terminal domain was modified to incorporate both the VSV peptide epitope tag and the SNAP protein tag sequences. This was cloned into the doxycycline-inducible locus of Flp-In™ TREX™ 293 cells and a transfected population selected. Doxycycline-regulated expression of this construct was assessed in three distinct ways. Firstly, immunoblotting with an anti-SNAP/CLIP antiserum of SDS-PAGE resolved lysates of cells that had been maintained for 24 h in the presence of different concentrations of doxycycline identified specific induction of the receptor construct as a polypeptide with apparent molecular mass in the region of 80 kDa (Fig. 1A). No equivalent species was detected either in lysates of these cells grown in the absence of doxycycline or in lysates of parental, non-transfected Flp-In™ TREX™ 293 cells (Fig. 1A). Secondly, doxycycline-induced expression and effective cell surface delivery of the construct was defined by fluorescence emission at 620 nm following excitation at 337 nm, subsequent to adding the SNAP-tag label SNAP-Lumi4Tb to intact cells. This reflects covalent attachment of the label to the SNAP tag of the construct. This is located in the extracellular milieu because the N-terminal domain of cell surface targeted GPCRs is anticipated to be outside the cell (Fig. 1B). Third, specific binding of concentrations of the muscarinic antagonist [3H]QNB, close to
Regulation of Muscarinic Receptor Oligomers

![Diagram](Image)

**FIGURE 2. Characterization of hM3 RASSL expression.** HA-CLIP-hM3 RASSL was cloned into the Flp-In™ T-REx™ locus of Flp-In™ T-REx™ 293 cells and a population of stably transfected cells isolated. A, lysates of these cells, maintained for 24 h in the absence or presence of 10 ng·ml⁻¹ doxycycline, were prepared and resolved by SDS-PAGE. These were then immunoblotted with either anti-SNAP/CLIP (left hand side) or anti-HA (right hand side). See “Results” for further details. B, akin to Fig. 1 intact Flp-In™ T-REx™ 293 cells harboring HA-CLIP-hM3 RASSL and treated for 24 h with the indicated concentrations of doxycycline were treated with CLIP Lumi4Tb (10 nM). After washing, fluorescence emission at 620 nm following excitation at 337 nm defined the relative expression levels of HA-CLIP-hM3 RASSL at the cell surface. C, membrane preparations from cells as in B were used to define the specific binding of [³H]QNB (14–20 nM in individual experiments). Data are means ± S.E., n = 3. Note: the substantially higher concentration of [³H]QNB used than in Fig. 1 reflects the loss in binding affinity of antagonists associated with the RASSL version of hM3.

the $K_d$ as assessed in saturation binding studies ($0.30 \pm 0.07$ nM, mean ± S.E., n = 4), to membranes of doxycycline-induced VSV-SNAP-hM2WT cells generated a qualitatively similar profile as labeling of the construct with SNAP-Lumi4Tb (Fig. 1C).

We have previously characterized VSV- and SNAP-tagged forms of both the WT muscarinic hM3 acetylcholine receptor and a chemically engineered, Receptor Activated Solely by Synthetic Ligand (RASSL) variant (4, 23–24). This form is not able to bind or respond effectively to acetylcholine or related synthetic analogs. Rather, it is activated by the usually inert chemical ligand clozapine N-oxide (CNO) (23–24). Now, a modification of this construct to generate HA-CLIP-hM3 RASSL in which the N-terminal VSV- and SNAP-tags were replaced with the HA peptide epitope tag and the CLIP protein tag sequence was generated. This was also cloned into the doxycycline-inducible locus of Flp-In™ T-REx™ 293 cells. Doxycycline-induced expression and cell surface delivery of this construct was also characterized by immunoblotting to detect each of the CLIP- and HA-tags (Fig. 2A) and, now, by the binding of CLIP-Lumi4Tb (Fig. 2B). As anticipated from the substantially larger third intracellular loop of the hM3 receptor compared with hM2, the apparent molecular mass of the predominant form of HA-CLIP-hM3 RASSL identified by the SNAP/CLIP antiserum was in the region of 110 kDa (Fig. 2A). Such RASSL forms of muscarinic receptors display modestly reduced affinity for many antagonist ligands (24), including [³H]QNB, compared with the equivalent WT receptor. Preliminary studies indicated the $K_d$ of [³H]QNB for HA-CLIP-hM3 RASSL to be in the region of 2.5 nM. Therefore, by measuring the specific binding of a substantially higher concentration of [³H]QNB (15 nM) than used for VSV-SNAP-hM2 WT it was also possible to quantify expression of HA-CLIP-hM3 RASSL (Fig. 2C). Noticeably, although the anti-SNAP/CLIP antiserum identified two forms of HA-CLIP-hM3 RASSL, the HA antiserum identified only the more rapidly migrating and less prominent form (Fig. 2A). Pre-treatment of cells during the period of receptor induction with the de novo N-glycosylation inhibitor tunicamycin demonstrated the form with lower mobility, which was not identified by the anti-HA antiserum, to be the mature N-glycosylated form. Moreover, equivalent studies indicated that VSV-SNAP-hM2 WT was also N-glycosylated in the absence of tunicamycin treatment (Fig. 3) and that these mature forms of the receptors were the predominant species present.

In cells induced to express VSV-SNAP-hM2 WT addition of a single concentration of SNAP-Lumi4Tb, as potential energy donor, along with varying concentrations of SNAP-Red, as potential energy acceptor, generated bell-shaped homogeneous time-resolved (htr)FRET signals. These were detected as emission at 665 nm following excitation at 337 nm and are consistent with VSV-SNAP-hM2 WT existing, at least in part, as cell surface homo-dimers/oligomers (Fig. 4A) (4). By contrast, no such signals were produced in the absence of doxycycline-induced receptor expression (Fig. 4A). To define that these htrFRET signals reflected relevant homomeric protein-protein interactions, and not simply proximity due to the level of receptor expression causing crowding or bystander effects, we performed equivalent experiments in Flp-In™ T-REx™ 293 cells able to express the monomeric transmembrane protein CD86...
The polyepitope was also modified to introduce both the VSV- and SNAP-tag sequences into the extracellular N-terminal domain. Here, addition of a combination of SNAP-Lumi4Tb and varying concentrations of SNAP-Red did not result in significant htrFRET signal in cells induced to express VSV-SNAP-CD86. Indeed, the signal was indistinguishable from cells in which expression of this construct was not induced (Fig. 4A). These experiments were carefully designed to result in cell surface expression of the same amount of VSV-SNAP-CD86 as VSV-SNAP-hM2WT. This was measured directly by the level of binding of SNAP-Lumi4Tb to each of the receptors, as in Fig. 1B, as fluorescence at 620 nm following excitation as 337 nm (Fig. 4B). Therefore, VSV-SNAP-hM2WT is present within homo-oligomers at expression levels in which such signals are not produced by a well characterized monomeric protein.

Addition of a single concentration of CLIP-Lumi4Tb, as potential energy donor, along with varying concentrations of CLIP-Red to cells induced to HA-CLIP-hM3RASSL also generated bell-shaped htrFRET signals (Fig. 4C). This was lacking in cells not induced to express HA-CLIP-hM3RASSL (Fig. 4C). These results also are consistent with homo-dimeric/oligomeric HA-CLIP-hM3RASSL interactions (Fig. 4C), confirming previous reports of hM3-hM3 interactions (4).

To explore the potential for co-expressed hM2 and hM3 to exist within heteromeric complexes, cells able to express VSV-SNAP-hM2WT only following addition of doxycycline, were further transfected with HA-CLIP-hM3RASSL and clones constitutively expressing this receptor variant isolated. A substantial number of clones were characterized in preliminary studies. These identified examples in which the levels of constitutively expressed HA-CLIP-hM3RASSL remained constant while expression of varying levels of VSV-SNAP-hM2WT could be achieved by cell maintenance in the presence of different concentrations of doxycycline. A representative clone is shown in Fig. 5. Cell surface VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL were imaged individually following addition of the cell impermeant dyes SNAP-surface 549 or CLIP-surface 488. As shown in Fig. 5A the CLIP-tagged receptor was present both with and without doxycycline treatment while the SNAP-tagged receptor was only present following doxycycline treatment. Merging of these images indicated clear co-localization of the two receptors at the resolution of light microscopy (Fig. 5A). Levels of binding of CLIP-Lumi4Tb (reflecting the presence of HA-CLIP-hM3RASSL) to these cells were constant over a range of doxycycline concentrations. By contrast, binding of SNAP-Lumi4Tb (reflecting the appearance of VSV-SNAP-hM2WT) increased with increasing concentrations of doxycycline (Fig. 5B). To better quantify the relative levels of VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL expression we measured the specific binding of $[^{3}H]$QNB. Concentrations (16–21.6 nM in individual experiments) were cal-
culated to occupy some 87–90% of HA-CLIP-hM₃RASSL and more than 98% of VSV-SNAP-hM₂WT in membranes prepared from cells treated or not with doxycycline. This defined that HA-CLIP-hM₃RASSL was present at 1632 / H₁₁₀₀₆ / 650 fmol / H₁₈₅₂₈ / 18528 mg protein / H₁₁₀₀₂ / 1. Moreover, because after treatment with 5 ng / H₁₈₅₂₈ / ml / H₁₁₀₀₂ / 1 doxycycline the combined level of expression of muscarinic receptors was 4678 / H₁₁₀₀₆ / 1481 fmol / H₁₈₅₂₈ / 18528 mg protein / H₁₁₀₀₂ / 1 (Fig. 5 C), these studies indicated the hM₂WT could be expressed at up to twice the total level of hM₃RASSL. In parallel sets of immunoblots of SDS-PAGE-resolved samples, anti-VSV antibodies only detected protein of the appropriate molecular mass, corresponding to VSV-SNAP-hM₂WT, following treatment of the cells with doxycycline (Fig. 5 D). Immunoblots using the combined anti-SNAP/CLIP antiserum confirmed that a polypeptide(s) in the region of 80 kDa (VSV-SNAP-hM₂WT) was expressed in a doxycycline-dependent manner by these cells, while a polypeptide(s) in the region of 110 kDa (HA-CLIP-hM₃RASSL) was expressed constitutively (Fig. 5 D).

Using these cells, without doxycycline treatment, homomeric HA-CLIP-hM₃RASSL interactions were clearly detected as htrFRET signal at 665 nm following addition of combinations of CLIP-Lumi4Tb and CLIP-Red (Fig. 6 A). Interestingly, such interactions were maintained when the VSV-SNAP-hM₂WT construct was also expressed, i.e. following treatment with doxycycline (Fig. 6 A). By contrast, and as anticipated, no htrFRET signal corresponding to VSV-SNAP-hM₂WT ho-

**FIGURE 5.** Characterization of cells able to co-express hM₂WT and hM₃RASSL. Cells, as in Fig. 1, able to express VSV-SNAP-hM₂WT in a doxycycline-dependent fashion were further transfected with HA-CLIP-hM₃RASSL and clones expressing this receptor construct isolated. One specific clone is detailed. A, cells were maintained in the absence or presence of 5 ng·ml⁻¹ doxycycline for 24 h and then either of the cell impermeable dyes, SNAP-surface 549 (to label cell surface hM₂WT) and CLIP-surface 488 (to label cell surface hM₃RASSL), was added and the cells imaged. Where indicated the images corresponding to SNAP-surface 549 and CLIP-surface 488 labeling were merged. B, cells were maintained in the absence or presence of varying concentrations of doxycycline for 24 h. Subsequently either SNAP Lumi4Tb (open bars) or CLIP Lumi4Tb (filled bars) was added and fluorescence emission at 620 nm after excitation at 337 nm was measured to assess relative levels of cell surface VSV-SNAP-hM₂WT and HA-CLIP-hM₃RASSL (n = 6–8 for each doxycycline concentration). C, specific [³H]QNB binding to membranes from cells maintained in the absence or presence of 5 ng·ml⁻¹ doxycycline was assessed. Note: individual experiments were performed with 16–21.6 nM [³H]QNB to allow effective detection of hM₃RASSL as well as hM₂WT and resulted in poorer data quality due to the relatively poor specific to nonspecific binding ratios at these high concentrations of [³H]QNB (means ± S.E., n = 4). D, immunoblots were performed on membranes prepared from either these cells maintained in the presence of the indicated concentrations of doxycycline for 24 h or from parental Flp-In™ TREx™ 293 cells (Flp-In). Panels display anti-VSV (hM₂WT) (left hand panel) or anti-SNAP/CLIP (both hM₂WT and hM₃RASSL) (right hand panel) immunoreactivity.
Detection of homomers of both hM2WT and hM3RASSL as well as hM2WT-hM3RASSL heteromers in cells expressing both muscarinic receptor subtypes. Cells, as in Fig. 5, expressing HA-CLIP-hM3RASSL in a constitutive manner and able to express VSV-SNAP-hM2WT in a doxycycline-dependent fashion were employed. A, htrFRET studies using combinations of CLIP-Lumi4Tb and CLIP-Red demonstrate the presence of hM3RASSL homomers only after treatment with doxycycline (filled symbols) and presence (open symbols) of hM2WT. B, htrFRET studies using combinations of SNAP-Lumi4Tb and SNAP-Red demonstrate the presence of hM2WT homomers only after treatment with doxycycline (open symbols) and the expression of VSV-SNAP-hM2WT receptor. No such interactions were detected without receptor induction (filled symbols). C, addition of combinations of either SNAP-Lumi4Tb and CLIP-Red (circles) or CLIP-Lumi4Tb and SNAP-Red (squares) followed by htrFRET analysis shows also the presence of hM2WT-hM3RASSL heteromers when the two receptor subtypes are co-expressed. D, lysates of untreated cells (−Dox) or those treated with doxycycline (+) for various periods and maintained in the presence of the N-glycosylation inhibitor tunicamycin (Tun) were immunoprecipitated with anti-HA to detect co-immunoprecipitation of HA-CLIP-hM3RASSL. As induction of expression of VSV-SNAP-hM2WT requires a significant period of time after addition of doxycycline, co-immunoprecipitation is only observed at the later time points. Note: As shown in Fig. 1, anti-HA is only able to identify the non-N-glycosylated form of HA-CLIP-hM3RASSL. This is why experiments were performed in tunicamycin-treated cells.

Regulation of Muscarinic Receptor Oligomers

FIGURE 6. Detection of homomers of both hM2WT and hM3RASSL as well as hM2WT-hM3RASSL heteromers in cells expressing both muscarinic receptor subtypes. Cells, as in Fig. 5, expressing HA-CLIP-hM3RASSL in a constitutive manner and able to express VSV-SNAP-hM2WT in a doxycycline-dependent fashion were employed. A, htrFRET studies using combinations of CLIP-Lumi4Tb and CLIP-Red demonstrate the presence of hM3RASSL homomers only after treatment with doxycycline (filled symbols) and presence (open symbols) of hM2WT. B, htrFRET studies using combinations of SNAP-Lumi4Tb and SNAP-Red demonstrate the presence of hM2WT homomers only after treatment with doxycycline (open symbols) and the expression of VSV-SNAP-hM2WT receptor. No such interactions were detected without receptor induction (filled symbols). C, addition of combinations of either SNAP-Lumi4Tb and CLIP-Red (circles) or CLIP-Lumi4Tb and SNAP-Red (squares) followed by htrFRET analysis shows also the presence of hM2WT-hM3RASSL heteromers when the two receptor subtypes are co-expressed. D, lysates of untreated cells (−Dox) or those treated with doxycycline (+) for various periods and maintained in the presence of the N-glycosylation inhibitor tunicamycin (Tun) were immunoprecipitated with anti-HA to detect co-immunoprecipitation of HA-CLIP-hM3RASSL. As induction of expression of VSV-SNAP-hM2WT requires a significant period of time after addition of doxycycline, co-immunoprecipitation is only observed at the later time points. Note: As shown in Fig. 1, anti-HA is only able to identify the non-N-glycosylated form of HA-CLIP-hM3RASSL. This is why experiments were performed in tunicamycin-treated cells.

Homomers was detected in the absence of doxycycline, because this receptor is absent. However, htrFRET signal corresponding to VSV-SNAP-hM2WT homomers appeared at the cell surface following doxycycline treatment of the cells (Fig. 6B). Importantly, in the doxycycline-induced cells addition of combinations of SNAP-Lumi4Tb and CLIP-Red also demonstrated the proximity of hM2WT and hM3RASSL, potentially within heteromeric oligomers (Fig. 6C). Moreover, hM2WT-hM3RASSL hetero-interactions were also detected when the labeling protocol was reversed to use a combination of CLIP-Lumi4Tb and, therefore, HA-CLIP-hM3RASSL as the energy donor, and SNAP-Red and, therefore, VSV-G-SNAP hM2WT as energy acceptor (Fig. 6C). Immunoprecipitation of VSV-SNAP-hM2WT with anti-VSV antibodies resulted in co-immunoprecipitation of anti-HA immunoreactivity, corresponding to HA-CLIP-hM3RASSL, only after doxycycline treatment had resulted in the co-expression of the two receptors (Fig. 6D).

hM2 is linked predominantly to Pertussis toxin-sensitive, Gq-family G proteins while hM3 is usually largely associated with signaling via Gq,11-family G proteins. Moreover, although the acetylcholine mimetic carbachol is able to activate WT muscarinic receptors, it is reported to display very low potency at RASSL forms of this receptor family (23, 24). This was confirmed in cells induced to express VSV-SNAP hM2WT in the constitutive presence of HA-CLIP-hM3RASSL. Here carbachol was able to effectively inhibit forskolin-stimulated cAMP production with pEC50 = 6.9 ± 0.1 (mean ± S.E., n = 4). However, in cells not induced to express VSV-SNAP-hM2WT and, therefore, with only HA-CLIP-hM3RASSL present, little inhibition of forskolin-stimulated cAMP levels was noted at concentrations of carbachol up to 1 μM (Fig. 7A). By contrast, both in the absence (pEC50 = 8.10 ± 0.08) and presence (pEC50 = 8.00 ± 0.18) (means ± S.E., n = 5 in each case) of VSV-SNAP hM2WT, CNO was able to potentially stimulate the production of inositol monophosphates (Fig. 7B). This is a downstream indicator of Gq,11 activation. Interestingly, although not reaching statistical significance, there was a trend toward higher inositol monophosphate production in response to CNO when the two receptors were co-expressed (Fig. 7B). This did not reflect a direct effect of CNO on the hM2WT receptor orthosteric binding pocket because neither with nor without doxycycline induction was carbachol able to cause a significant accumulation of inositol monophosphates in these cells (Fig. 7B). Importantly, however, these studies did define the functionality of the expressed constructs and confirmed the previously established selectivity of the agonist ligands in this setting (23, 24).

Potential effects of ligands on the organization or stability and regulation of GPCR oligomers is a complex topic in which a range of observations have been reported (11). In cells induced with doxycycline to allow co-expression of VSV-SNAP-hM2WT and HA-CLIP-hM3RASSL, as noted above, co-addition of a combination of SNAP-Lumi4Tb and CLIP-Red resulted in detection of htrFRET signal, consistent with interactions between the two receptors (Fig. 8A). Over a period of 40 min, exposure to a concentration (10 μM) of the muscarinic antagonist atropine that is sufficient to occupy fully both the hM2WT and hM3RASSL constructs, had no greater effect on the heteromer signal than addition of vehicle (Fig. 8A). By con-
Regulation of Muscarinic Receptor Oligomers

A

![Graph A](image)

B

![Graph B](image)

FIGURE 7. hM2WT and hM3RASSL constructs display the anticipated pharmacological selectivity. Cells constitutively expressing HA-CLIP-hM3RASSL and harboring VSV-SNAP-hM2WT at the doxycycline-inducible locus were maintained in the absence (filled symbols) or presence (open symbols) of 5 ng/ml doxycycline for 24 h. Subsequently cells were employed to measure the ability of carbachol (Cch) (circles) or CNO (squares) to produced inhibition of forskolin-stimulated cAMP levels (A) or the capacity of either CNO or carbachol to mediate increases in levels of inositol monophosphates (B).

Discussion

Although it is well established that monomers of the individual subtypes of muscarinic acetylcholine receptors can exist in proximity to one another (4, 26–28) and, indeed, have the capacity to generate dimers and/or higher-order oligomers (6–7, 9, 18, 27–28), a broad range of issues around such interactions remain unresolved. Among these are the stability (19) or otherwise (8, 18) of dimeric interactions, the overall dimensions and organization of dimeric/oligomeric complexes (7, 9, 25) and the implications of this for the details of interaction with heterotrimeric G proteins and downstream signal transduction (11–12). Moreover, as muscarinic subtypes are expressed at markedly different levels in different cells and tissues this may, as suggested by some (25) but not other (19–20) reports on both muscarinic and other rhodopsin-like family GPCRs, affect the extent of their dimerization/oligomerization. Furthermore, distinct muscarinic receptor subtypes may be coexpressed in physiologically relevant cells (29–30). Although the capacity for heteromeric interactions between various muscarinic receptor pairs has been explored to some degree (26–27), the propensity for this to occur concurrently with homomerization, and its implications for function, have been little explored to date. For example, M2 and M3 receptors are co-expressed in smooth muscle but the functional importance of this for the integration of signaling remains uncertain. Within the current studies we have, therefore, addressed a number of these issues by combinations of biochemical, biophysical, and chemical biology approaches.

Central to these studies was the use of cell surface htrFRET, based on the incorporation of SNAP- and CLIP-tags (31–32), into various muscarinic receptor constructs. Such tagging allowed the covalent incorporation of htrFRET-competent fluorophores into the extracellular N-terminal region of the receptors via linkage to the engineered SNAP and CLIP protein tags. Importantly, such large scale modification of the N-termi-
nal domain of either the hM2 or hM3 receptor did not affect their basic ligand pharmacology. Of equal importance was the introduction of RASSL-inducing mutations into the hM3 receptor constructs (23–24). Particularly for the muscarinic receptor family, such modified GPCRs are also frequently denoted as DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) (33). The associated alteration in agonist pharmacology so produced allowed for selective agonist occupancy and activation of the hM2 WT receptor (with the acetylcholine mimetic carbachol) and the hM3 RASSL receptor (with the muscarinic RASSL agonist CNO) in cells co-expressing the two receptor subtypes. This was confirmed by demonstrating both that carbachol-mediated inhibition of cAMP levels was observed only following induced expression of the hM2 receptor and not when the hM3 RASSL receptor was expressed alone, and that CNO, but not carbachol, was able to promote the production of inositol monophosphates via the hM3 RASSL receptor, both in the absence and presence of the hM2 WT receptor. By contrast, the antagonist atropine was able to bind to both receptors with similar affinity.

In cells able to express only either the SNAP-tagged hM2 WT receptor or the CLIP-tagged RASSL form of the hM3 receptor, htrFRET studies provided clear evidence for homomeric interactions of each subtype. Although this was anticipated from previous work, in cells constitutively expressing hM3 RASSL receptors, induced expression of the hM2 WT receptor now resulted in detection of hM2-hM2 interactions as well as hM2-hM3 interactions at the surface of these cells without eliminating hM3-hM3 interactions. The most obvious interpretation of these results is that receptor homomers can co-exist with relevant heteromers perhaps, as suggested by Herrick-Davis et al., as stable and distinct dimers (20). However, it is important to note that others have suggested such interactions to be more dynamic (18, 34). Moreover, concurrent monitoring of hM2-hM2 and hM2-hM3 interactions in dual color studies, in which a single energy donor and two distinct energy acceptor reagents were added concurrently, also provided evidence for each of these interactions. This is the first time that such an approach has been used to examine multiple interaction partners of a GPCR simultaneously.

A common concern in studies on interactions involving cell surface transmembrane proteins is that high level expression may result in apparent interactions based on proximity that reflect the levels of expression achieved. We addressed this in two distinct ways. Firstly, for all the studies performed we generated and utilized stably transfected cell lines able to express the receptor(s) of interest in a controlled, inducible manner. Generally, studies that rely entirely on transient transfection protocols encounter challenges due to high level expression of the receptor(s) often incompletely processed, within subsets of the cell population. Herein, we demonstrated that the bulk of each of the muscarinic receptor subtype constructs was appropriately N-glycosylated, as anticipated for mature, correctly trafficked GPCRs. More importantly we also generated an
equivalent cell line able to inducibly express VSV-SNAP-CD86. CD86 is recognized as a monomeric single transmembrane domain protein (25). Expression of this construct to the same level as used to study VSV-SNAP-hM2WT generated no specific htrFRET signal upon addition of a combination of SNAP-tag energy donor and acceptor species. This provided comfort that the signals produced at these levels of expression of VSV-SNAP-hM2WT did indeed reflect true receptor-receptor interactions.

The further key outcome of these studies is that the agonist carbachol was able to change energy transfer signals corresponding to both hM2-hM2 and hM2-hM3 interactions. By contrast this ligand had no effects on hM3-hM3 interactions. This latter feature was hardly surprising as the hM3RASSL constructs used in these studies were modified to have minimal affinity for carbachol (23–24). However, in the case of the hM2-hM3 and hM2-hM4 interactions the directionality of the effect of carbachol was completely different. Both in cells expressing only the hM2WT receptor construct, and those expressing both the hM2WT and the hM4RASSL receptors, carbachol increased the htrFRET signal corresponding to hM2-hM2 homomers and did so in both a time- and concentration-dependent manner. Moreover, the EC_{50} for the ligand in producing these changes in htrFRET was very similar to the affinity of carbachol at the hM2WT receptor. This is consistent with the effects reflecting receptor occupancy. By contrast carbachol decreased the htrFRET signal corresponding to hM2WT-hM3RASSL interactions. This was, however, once again both time- and concentration-dependent. It could be argued in the hM2-hM3 co-expression that the effect of carbachol was to diminish hM2-hM3 interactions and that this then resulted in greater hM2-hM3 interactions, i.e. to promote a heteromer to homomer transition. However, although these effects of carbachol could also be detected in triple labeling, ‘dual color’ studies in which the effects on the receptor complexes were measured concurrently, further studies will be required to support such a conclusion. Perhaps surprisingly, unlike carbachol, CNO was currently, further studies will be required to support such a conclusion. Perhaps surprisingly, unlike carbachol, CNO was unable to influence htrFRET signals corresponding to hM2-
RASSL-hM3RASSL interactions to any greater extent than addition of vehicle. This may reflect greater stability of hM2-hM3 homomeric interactions compared with either hM2-hM2 homomers or hM2-hM3 heteromers. However, although identified as a highly selective activator of RASSL forms of muscarinic receptor subtypes, CNO is of course not a direct equivalent of carbachol. This is despite CNO acting as an apparently high efficacy agonist that, in a wide range of assays, shows broad similarity in capacity to activate and regulate the hM2RASSL as either carbachol or acetylcholine do at the wild type hM3 receptor (23). Although there may be differences in details of efficacy or bias of CNO at the hM2RASSL receptor end points that have not been assessed previously that may account for this difference, a distinct explanation is that the hM2 and hM3 receptors differ in the basis or stability of their homomeric interactions. It is notable in this regard that Calebiro et al. have provided evidence for markedly different stability and propensity of β1- and β2-adrenoceptors to form dimers and higher-order oligomers (25), even though these receptors are highly homologous and are activated by the same hormones. This is not the first set of studies to suggest a capacity of ligand to alter the organization and/or stability of a muscarinic receptor homomer. Although muscarinic toxin 7, a highly selective allosteric peptide ligand of the M1 subtype, binds (35–36) in a very different manner to carbachol or CNO (23), it has been reported to stabilize M1 receptor homomers (35–36). It has also been suggested that the selective M1 receptor antagonist pirenzepine can promote dimerization of this receptor (37).

Beyond possible differences in efficacy, one further observation that is difficult to provide a clear explanation for was the marked difference in the effects of carbachol and CNO on hM2WT-hM3RASSL interactions and, thus, on hM2-hM3 heteromers. Although difficult to demonstrate without making further alterations in the ligand binding pocket to alter ligand pharmacology, as has been done for the β2-adrenoreceptor (38) and the leukotriene B(4) receptor (39), which, to some extent invalidates the basis of the experiment, it is anticipated that a ligand effect across the interface of a receptor homo-dimer/oligomer should be symmetric. Therefore, an effect of ligand binding to one protomer is anticipated to be reciprocated by (the same) agonist occupancy of the other protomer. Herein, carbachol effects on hM2WT-hM3RASSL receptor interactions were not recapitulated by CNO. This may simply reflect that the hM2 and hM3 receptors are, of course, distinct species or that the makeup of hM2WT-hM3RASSL receptor heteromers is not simply 1:1 in oligomeric (7, 28) rather than dimeric configurations. No matter the basis for the lack of symmetry here, this is topic that requires and deserves further consideration in the future.

Notwithstanding this final point, the current studies offer a broad range of novel insights into differences in ligand regulation of hM2-hM3 versus hM2-hM3 interactions and provide a one donor plus two acceptors strategy to concurrently assess interactions of a protein with more than a single partner. The molecular basis for the noted differences in ligand regulation between closely related receptors will provide a drive for future analysis.

References
1. Heinrich, J. N., Butera, J. A., Carrick, T., Kramer, A., Kowal, D., Lock, T., Marquis, K. L., Prausnitz, M. H., Popielok, M., Sun, S. C., Tseng, E., Uveges, A. J., and Mayer, S. C. (2009) Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-prefering receptor agonists. *Eur. J. Pharmacol.* 595, 53–56.
2. Haga, K., Kruse, A. C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W. I., Okada, T., Kobikla, B. K., Haga, T., and Kobayashi, T. (2012) Structure of the human M3 muscarinic acetylcholine receptor bound to an antagonist. *Nature* 482, 547–551.
3. Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. F., Liu, T., Chae, P. S., Dror, R. O., Shaw, D. E., Weis, W. I., Wess, J., and Kobikla, B. K. (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. *Nature* 482, 552–556.
4. Alvarez-Curto, E., Ward, R. J., Pediani, J. D., and Milligan, G. (2010) Ligand regulation of the quaternary organization of cell surface M3 muscarinic acetylcholine receptors analyzed by fluorescence resonance energy transfer (FRET) imaging and homogenous time-resolved FRET. *J. Biol. Chem.* 285, 23318–23330.
5. McMillin, S. M., Heusel, M., Liu, T., Costanzi, S., and Wess, J. (2011) Structural basis of M3 muscarinic receptor dimer/oligomer formation. *J. Biol. Chem.* 286, 28584–28598.
6. Hu, J., Xu, D., Zhou, Y., Liu, T., Wang, Y., McMillin, S. M., Mistry, R., Challiss, R. A., Costanzi, S., and Wess, J. (2012) Structural aspects of M3 muscarinic acetylcholine receptor dimer formation and activation. *FASEB J.* 26, 604–616.
7. Patowary, S., Alvarez-Curto, E., Xu, T. R., Holz, J. D., Oliver, J. A., Milligan, G., and Raicu, V. (2013) The muscarinic M3 acetylcholine receptor exists as two differently sized complexes at the plasma membrane. *Biochim. Biophys. Acta* 1812, 303–312.
8. Nenasheva, T. A., Neary, M., Masonov, G. I., Birdsall, N. J., Breckenridge, R. A., and Molloy, J. E. (2013) Abundance, distribution, mobility and oligomeric state of M3 muscarinic acetylcholine receptors in live cardiac muscle. *J. Mol. Cell. Cardiol.* 57, 129–136.
9. Redka, D. S., Morizumi, T., Elmslie, G., Paranatham, P., Shivaraina, R. V., Ellis, J., Ernst, O. P., and Wells, J. W. (2014) Coupling of G proteins to reconstituted monomers and tetramers of the M3 muscarinic receptor. *J. Biol. Chem.* 289, 24347–24365.
10. Pin, J. P., Neubig, R., Bouvier, M., Devi, L., Filizola, M., Javitch, J. A., Lobhe, M. J., Milligan, G., Palzewski, K., Parmentier, M., and Spedding, M. (2007) International union of basic and clinical pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromers. *Pharmacol. Rev.* 59, 5–13.
11. Milligan, G. (2013) The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization. *Mol. Pharmacol.* 84, 158–169.
12. Ferré, S., Casado, V., Devi, L. A., Filizola, M., Jockers, R., Lobhe, M. J., Milligan, G., Pin, J. P., and Guitart, X. (2014) G Protein-Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives. *Pharmacol. Rev.* 66, 413–434.
13. Manglik, A., Kruse, A. C., Kobikla, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. L., Kobikla, B. K., and Granier, S. (2012) Crystal structure of the mu-opioid receptor bound to a morphinan antagonist. *Nature* 485, 321–326.
14. Huang, J. Y., Chen, S., Zhang, J. Y., and Huang, X. Y. (2013) Crystal structure of oligomeric β-1-adrenergic G protein-coupled receptors in ligand-free state. *Nat. Struct. Mol. Biol.* 20, 419–425.
15. Zhang, K. H., Zhang, J., Gao, Z. G., Zhang, D., Zhu, L., Han, G. W., Moss, S. M., Paolotta, S., Kiselev, E., Lu, W., Fenalti, G., Zhang, W., Müller, C. E., Yang, H., Jiang, H., Cherezov, V., Katritch, V., Jacobson, K. A., Stevens, R. C., Wu, B., and Zhao, Q. (2014) Structure of the human P2Y12 receptor in complex with an antithrombotic drug. *Nature* 509, 115–118.
16. Whorton, M. R., Bokoch, M. P., Rasmussen, S. G., Huang, B., Zare, R. N., Kobikla, B., and Sunahara, R. K. (2007) A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. *Proc. Natl. Acad. Sci. U.S.A.* 104, 7682–7687.
17. Kuszak, A. J., Pitchiya, S., Anand, J. P., Mosberg, H. I., Walter, N. G., and Sunahara, R. K. (2009) Purification and Functional Reconstitution of Mo-
Regulation of Muscarinic Receptor Oligomers

14. Herrick-Davis, K., Grinde, E., Cowan, A., and Mazurkiewicz, J. E. (2013) Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: The oligomer number puzzle. *Mol. Pharmacol.* **84**, 630–642

15. Gavalas, A., Lan, T. H., Liu, Q., Corrêa, I. R., Jr., Javitch, J. A., and Lambert, N. A. (2013) Segregation of family A G protein-coupled receptor protomers in the plasma membrane. *Mol. Pharmacol.* **84**, 346–352

16. Pou, C., la Cour, C. M., Stoddart, L. A., Millan, M. J., and Milligan, G. (2012) Functional Homomers and Heteromers of Dopamine D_{1} and D_{3} Receptors Co-exist at the Cell Surface. *J. Biol. Chem.* **287**, 8864–8878

17. Alvarez-Curto, E., Prihandoko, R., Tautermann, C. S., Zwier, J. M., Pediani, J. D., Lohse, M. J., Hoffmann, C., Tobin, A. B., and Milligan, G. (2011) Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). *Mol. Pharmacol.* **80**, 1033–1046

18. Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S., and Roth, B. L. (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potentely activated by an inert ligand. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 5163–5168

19. Calebido, D., Rieken, F., Wagner, J., Sungkaworn, T., Zabel, U., Borzi, A., Cocucci, E., Zürn, A., and Lohse, M. J. (2013) Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 743–748

20. Goin, J. C., and Nathanson, N. M. (2006) Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells - Regulation of receptor down-regulation by heterodimerization. *J. Biol. Chem.* **281**, 5416–5425

21. Borroto-Escuela, D. O., García-Negredo, G., Garriga, P., Fuxe, K., and Ciruela, F. (2010) The M₄ muscarinic acetylcholine receptor third intracellular loop regulates receptor function and oligomerization. *Biochim Biophys Acta* **1803**, 813–825

22. Pou, C., la Cour, C. M., Stoddart, L. A., Millan, M. J., and Milligan, G. (2012) Functional Homomers and Heteromers of Dopamine D_{1} and D_{3} Receptors Co-exist at the Cell Surface. *J. Biol. Chem.* **287**, 8864–8878

23. Alvarez-Curto, E., Prihandoko, R., Tautermann, C. S., Zwier, J. M., Pediani, J. D., Lohse, M. J., Hoffmann, C., Tobin, A. B., and Milligan, G. (2011) Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). *Mol. Pharmacol.* **80**, 1033–1046

24. Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S., and Roth, B. L. (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potentely activated by an inert ligand. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 5163–5168

25. Calebido, D., Rieken, F., Wagner, J., Sungkaworn, T., Zabel, U., Borzi, A., Cocucci, E., Zürn, A., and Lohse, M. J. (2013) Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 743–748

26. Goin, J. C., and Nathanson, N. M. (2006) Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells - Regulation of receptor down-regulation by heterodimerization. *J. Biol. Chem.* **281**, 5416–5425

27. Borroto-Escuela, D. O., García-Negredo, G., Garriga, P., Fuxe, K., and Ciruela, F. (2010) The M₄ muscarinic acetylcholine receptor third intracellular loop regulates receptor function and oligomerization. *Biochim Biophys Acta* **1803**, 813–825

28. Pisterki, L. F., Jansma, D. B., Georgiou, J., Woodside, M. J., Chou, J. T., Angers, S., Raicu, V., and Wells, J. W. (2010) Oligomeric size of the M₂ muscarinic receptor in live cells as determined by quantitative fluorescence resonance energy transfer. *J. Biol. Chem.* **285**, 16723–16738

29. Struckmann, N., Schwerling, S., Wiegand, S., Gschnell, A., Yamada, M., Kummer, W., Wess, J., and Haberberger, R. V. (2003) Role of muscarinic receptor subtypes in the constriction of peripheral airways: Studies on receptor-deficient mice. *Mol. Pharmacol.* **64**, 1444–1451

30. Hamamura, M., Maróstica, E., de Avellar, M. C. W., and Porto, C. S. (2006) Muscarinic acetylcholine receptor subtypes in the rat seminal vesicle. *Mol. Endocrinol.* **24**, 192–198

31. Hussain, A. F., Amourey, M., and Barth, S. (2013) SNAP-tag technology: A powerful tool for site specific conjugation of therapeutic and imaging agents. *Curr. Pharm. Des.* **19**, 5437–5442

32. Kolberg, K., Puettmann, C., Pardo, A., Fitting, J., and Barth, S. (2013) SNAP-tag technology: a general introduction. *Curr. Pharm. Des.* **19**, 5406–5413

33. Urban, D. J., and Roth, B. L. (2015) DREADDs (Designer Receptors Exclusively Activated by Designer Drugs): Chemogenetic tools with therapeutic utility. *Annu. Rev. Pharmacol. Toxicol.* **55**, 399–417

34. Kasai, R. S., Suzuki, K. G., Prosnowitz, E. R., Koyama-Honda, I., Nakada, C., Fujiwara, T. K., and Kusumi, A. (2011) Full characterization of GPCR monomer-dimer dynamic equilibrium by single molecule imaging. *J. Cell Biol.* **192**, 463–480

35. Marquer, C., Frucht-Gaillard, C., Letellier, G., Marcon, E., Mourier, G., Zinn-Justin, S., Ménez, A., Servent, D., and Gilquin, B. (2011) Structural model of ligand-G protein-coupled receptor (GPCR) complex based on experimental double mutant cycle data: MT7 snake toxin bound to di-meric hM1 muscarinic receptor. *J. Biol. Chem.* **286**, 31661–31675

36. Marquer, C., Frucht-Gaillard, C., Mourier, G., Grandjean, O., Girard, E., Le Maire, M., Brown, S., and Servent, D. (2010) Influence of MT7 toxin on the oligomerization state of the M₃ muscarinic receptor. *Biol. Cell* **102**, 409–420

37. Ilien, B., Glasser, N., Clamme, J. P., Didier, P., Piemont, E., Chinnappan, R., Daval, S. B., Galzi, J. L., and Mely, Y. (2009) Pirenzepine promotes the dimerization of muscarinic M₁ receptors through a three-step binding process. *J. Biol. Chem.* **284**, 19533–19543

38. Sartania, N., Appelbe, S., Pediani, J. D., and Millaen, G. (2007) Agonist occupancy of a single monomeric element is sufficient to cause internalization of the dimeric β_{2}-adrenoceptor. *Cell. Signal.* **19**, 1928–1938

39. Damian, M., Mary, S., Martin, A., Pin, J. P., and Banères, J. L. (2008) G protein activation by the leukotriene B4 receptor dimer - Evidence for an absence of trans-activation. *J. Biol. Chem.* **283**, 21084–21092